Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,33773271,Tmax,PK data showed CSF MMF concentration 11% of plasma with Tmax of plasma at 5 hr and Tmax of CSF at 7 hr.,A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33773271/),h,5,627,DB08908,Dimethyl fumarate
,33773271,Tmax,PK data showed CSF MMF concentration 11% of plasma with Tmax of plasma at 5 hr and Tmax of CSF at 7 hr.,A pharmacokinetic and biomarker study of delayed-release dimethyl fumarate in subjects with secondary progressive multiple sclerosis: evaluation of cerebrospinal fluid penetration and the effects on exploratory biomarkers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33773271/),h,7,628,DB08908,Dimethyl fumarate
,27983793,PDI,"The developed DMF-tocopherol acetate NLCs offered an average size of 69.70 nm, PDI of 0.317, and a zeta potential of -9.71 mV.","Enhanced Brain Delivery of Dimethyl Fumarate Employing Tocopherol-Acetate-Based Nanolipidic Carriers: Evidence from Pharmacokinetic, Biodistribution, and Cellular Uptake Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27983793/),,0.317,78063,DB08908,Dimethyl fumarate
,27983793,zeta potential,"The developed DMF-tocopherol acetate NLCs offered an average size of 69.70 nm, PDI of 0.317, and a zeta potential of -9.71 mV.","Enhanced Brain Delivery of Dimethyl Fumarate Employing Tocopherol-Acetate-Based Nanolipidic Carriers: Evidence from Pharmacokinetic, Biodistribution, and Cellular Uptake Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27983793/),m,-,78064,DB08908,Dimethyl fumarate
,27983793,zeta potential,"The developed DMF-tocopherol acetate NLCs offered an average size of 69.70 nm, PDI of 0.317, and a zeta potential of -9.71 mV.","Enhanced Brain Delivery of Dimethyl Fumarate Employing Tocopherol-Acetate-Based Nanolipidic Carriers: Evidence from Pharmacokinetic, Biodistribution, and Cellular Uptake Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27983793/),m,9.71,78065,DB08908,Dimethyl fumarate
,26849839,recovery,"Quantitative determination of fampridine (FAM), teriflunomide (TFM) and dimethyl fumarate (DMF) was performed in human plasma with the recovery values in the range of 85-115%.","Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),%,85-115,116139,DB08908,Dimethyl fumarate
,26849839,flow rate,The method utilizes an XBridge C18 silica column and a gradient elution with mobile phase consisting of ammonium formate and acetonitrile at a flow rate of 0.5 mL min(-1) .,"Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),[ml] / [min],0.5,116140,DB08908,Dimethyl fumarate
,26849839,detection,"With LC-MS, the detection and quantification limits for all of the analytes were 1 and 5 ng, respectively.","Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),ng,1,116141,DB08908,Dimethyl fumarate
,26849839,q,"With LC-MS, the detection and quantification limits for all of the analytes were 1 and 5 ng, respectively.","Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),ng,1,116142,DB08908,Dimethyl fumarate
,26849839,q,"With LC-MS, the detection and quantification limits for all of the analytes were 1 and 5 ng, respectively.","Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26849839/),ng,5,116143,DB08908,Dimethyl fumarate
,9638311,tmax,"The absorption was faster in rats and rabbits than in dogs (tmax = 1 h or 6 h, respectively).","Absorption of the new anxiolytic compound deramciclane in rats, dogs and rabbits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638311/),h,1,202039,DB08908,Dimethyl fumarate
,9638311,tmax,"The absorption was faster in rats and rabbits than in dogs (tmax = 1 h or 6 h, respectively).","Absorption of the new anxiolytic compound deramciclane in rats, dogs and rabbits. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9638311/),h,6,202040,DB08908,Dimethyl fumarate
,30023324,zeta potential,"The optimized SLNs were characterized and found to have an average particle size of 300 nm, zeta potential value of -34.89 mv and polydispersity index value < 0.3.",Preparation and Statistical Modeling of Solid Lipid Nanoparticles of Dimethyl Fumarate for Better Management of Multiple Sclerosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30023324/),mv,-,235195,DB08908,Dimethyl fumarate
,30023324,zeta potential,"The optimized SLNs were characterized and found to have an average particle size of 300 nm, zeta potential value of -34.89 mv and polydispersity index value < 0.3.",Preparation and Statistical Modeling of Solid Lipid Nanoparticles of Dimethyl Fumarate for Better Management of Multiple Sclerosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30023324/),mv,34.89,235196,DB08908,Dimethyl fumarate
<,30023324,polydispersity index,"The optimized SLNs were characterized and found to have an average particle size of 300 nm, zeta potential value of -34.89 mv and polydispersity index value < 0.3.",Preparation and Statistical Modeling of Solid Lipid Nanoparticles of Dimethyl Fumarate for Better Management of Multiple Sclerosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30023324/),,0.3,235197,DB08908,Dimethyl fumarate
,30023324,Entrapment efficiency,Entrapment efficiency was found to be 59% and drug loading was 15%.,Preparation and Statistical Modeling of Solid Lipid Nanoparticles of Dimethyl Fumarate for Better Management of Multiple Sclerosis. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30023324/),%,59,235198,DB08908,Dimethyl fumarate
,30023324,drug loading,Entrapment efficiency was found to be 59% and drug loading was 15%.,Preparation and Statistical Modeling of Solid Lipid Nanoparticles of Dimethyl Fumarate for Better Management of Multiple Sclerosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30023324/),%,15,235199,DB08908,Dimethyl fumarate
